Society guideline links: Male infertility or hypogonadism

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Testosterone therapy in men" and "Society guideline links: Male sexual dysfunction".)

International

●Controversy and consensus on indications for sperm DNA fragmentation testing in male infertility – A global survey, current guidelines, and expert recommendations (2023)

●Controversy and consensus on the management of elevated sperm DNA fragmentation in male infertility – A global survey, current guidelines, and expert recommendations (2023)

●Endocrine Society (ES): Clinical practice guideline on testosterone therapy in men with hypogonadism (2018)

●International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) and the PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) Consortium: Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors (2017)

●International Society for the Study of the Aging Male (ISSAM): Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men (2015)

Canada

●Choosing Wisely Canada: Don't routinely perform sperm DNA fragmentation testing (updated 2022)

●Choosing Wisely Canada: Don’t order serum testosterone in men without symptoms of hypogonadism (updated 2020)

●Canadian Men's Health Foundation (CMHF): Diagnosis and management of testosterone deficiency syndrome in men – Clinical practice guideline (2015)

United States

●American Society for Reproductive Medicine (ASRM): Ethics committee opinions and webinars

●ASRM: Obesity and reproduction – A committee opinion (2021)

●American Urological Association (AUA) and ASRM: Guideline for the diagnosis and treatment of infertility in men (2020)

●ASRM: Evidence-based treatments for couples with unexplained infertility – A guideline (2020)

●ASRM: Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes – A committee opinion (2020)

●ASRM and Society for Assisted Reproductive Technology (SART): Intracytoplasmic sperm injection (ICSI) for non-male factor infertility – A committee opinion (2020)

●ASRM: Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy – A committee opinion (2019)

●American Society of Clinical Oncology (ASCO): Clinical practice guideline on fertility preservation in patients with cancer (2018)

●ASRM: Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility – A committee opinion (2018)

●ASRM: Smoking and infertility – A committee opinion (2018)

●AUA: Guidelines for the evaluation and management of testosterone deficiency (2018)

●US Food and Drug Administration (FDA): Testosterone information (updated 2015)

Europe

●European Association of Urology (EAU): Guidelines on sexual and reproductive health (2020, updated 2023)

●European Academy of Andrology (EAA): Guidelines on Klinefelter syndrome (2021)

●EAA: Guidelines on investigation, treatment and monitoring of functional hypogonadism in males (2020)

●European Society of Urogenital Radiology (ESUR): Ultrasound evaluation of varicoceles – Guidelines and recommendations for detection, classification, and grading (2020)

●EAA: Guideline – Management of oligo-astheno-teratozoospermia (2018)

●European consensus statement on congenital hypogonadotropic hypogonadism – Pathogenesis, diagnosis and treatment (2015)

●EAA and European Molecular Genetics Quality Network (EMQN): Best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions – State-of-the-art 2013 (published 2014)

●European Menopause and Andropause Society (EMAS): Position statement – Fertility preservation (2014)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Clinical guideline on fertility problems – Assessment and treatment (2013, updated 2017)

●NICE: Quality standard on fertility problems (2014)

●Scottish Intercollegiate Guidelines Network (SIGN): Long term follow up of survivors of childhood cancer (2013)

Australia–New Zealand

●Choosing Wisely Australia: Do not prescribe testosterone therapy to older men except in confirmed cases of hypogonadism

●Endocrine Society of Australia (ESA): Position statement on male hypogonadism (part 1) – Assessment and indications for testosterone therapy (2016)

●ESA: Position statement on male hypogonadism (part 2) – Treatment and therapeutic considerations (2016)

Japan

●[In Japanese] Japan Endocrine Society (JES) and Japan Men's Health Medical Association (JMHMA): Male hypogonadism guidelines (2022)

●[In Japanese] Japanese Society of Cancer Therapy (JSCT): Clinical guidelines for fertility preservation in pediatric, adolescent, and young cancer patients (2017)

●[In English] The Japanese Urological Association (JUA)/Japanese Society for the Study of the Aging Male (JSSAM): Clinical practice manual for late-onset hypogonadism syndrome (2008)